Windlas Biotech IPO will open for subscription from 04 August 2021. The company aims for an issue size of ₹401.54 Crore this IPO.
Also read: IPO List 2021: a complete list of IPOs in 2021
Windlas Biotech Limited
Incorporated in 2001, Windlas Biotech Ltd is one of the leading companies in the pharmaceutical formulations contract development and manufacturing organizations (CDMO) segment in India. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
It further sells its own branded products in the trade generics and OTC markets. Currently, the focus of the company is to launch complex generic products in the chronic therapeutic category related to lifestyle-related disorders. The business operates in 3 verticals; 1. CDMO Products and services, 2. Domestic trade generics and Over-the-counter (OTC) market (nutraceutical and health supplement products), and 3. Export.
Leading pharma companies i.e. Pfizer Ltd, Sanofi India Ltd, Cadila Healthcare Ltd, Emcure Pharmaceuticals Ltd, Eris Lifesciences Ltd, Intas Pharmaceuticals Ltd, and Systopic Laboratories Private Limited are some of the marquee customers of Windlas Biotech. Its manufacturing facilities are located at Dehradun with an installed operating capacity of 7,063.83 million tablets/ capsules, 54.46 million pouch/ sachet, and 61.08 million liquid bottles.
Objects of the Issue
- To purchase equipment required for capacity expansion of our existing facility at Dehradun Plant IV.
- To finance incremental working capital requirements of the company.
- Repayment/prepayment of the company’s borrowings.
- General corporate purposes.
Competitive strengths
- Leading market player in the domestic pharmaceutical formulation CDMO segment.
- Strong focus on the chronic therapeutic category.
- state-of-the-art manufacturing facilities in Dehradun, Uttarakhand.
- Professional and experienced Promoters and a senior management team.
- An innovative product portfolio of complex generic products.
- Robust financial performance track record.
Basic details about the company
| Full name | Windlas Biotech Limited |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Company Website | www.windlas.com |
Dates to remember
| IPO Open | 04 August 2021 |
| IPO Close | 06 August 2021 |
| Basis of Allotment | 11 August 2021 |
| Refunds date | 12 August 2021 |
| Credit to Demat Account | 13 August 2021 |
| Listing Date | 17 August 2021 |
IPO details
| Issue type | Book Building |
| IPO issue size | ₹401.54 Cr |
| Fresh Issue | ₹165.00 Cr |
| Offer for sale | ₹236.54 Cr |
| Face value | ₹5 per equity share |
| Price band | ₹448 to ₹460 per equity share |
| Retail Allocation | 35% |
| Lot size | 30 Shares |
| Minimum application | 1Lot-30 Shares |
| Maximum application | 14 Lots-420 Shares |
| Minimum application amount | ₹13,800 |
| Maximum application amount | ₹193,200 |
| Listing Exchange | BSE & NSE |
Company Financials
| Particulars | For the year/period ended (₹ in million) | |||
|---|---|---|---|---|
| 31-Dec-20 | 31-Mar-20 | 31-Mar-19 | 31-Mar-18 | |
| Total Assets | 3,158.83 | 3,384.88 | 2,981.80 | 2,898.87 |
| Total Revenue | 3,230.94 | 3,313.39 | 3,115.25 | 3,565.76 |
| Profit After Tax | 96.74 | 162.13 | 638.22 | 111.98 |
Valuation of Windlas Biotech (as of FY2020)
| Earnings Per Share (EPS) | ₹8.70 |
| Price/Earnings (PE ratio) | 51.49 – 52.87 |
| Return on Net Worth (RONW) | 18.19% |
| Net Asset Value (NAV) | ₹109.36 per share |
Company Promoters
- Ashok Kumar Windlass
- Hitesh Windlass
- Manoj Kumar Windlass
- AKW WBL Family Pvt Trust
Lead Managers
- DAM Capital Advisors Ltd (Formerly IDFC Securities Ltd)
- IIFL Holdings Limited
- SBI Capital Markets Limited
Windlas Biotech IPO Allotment Status
Windlas Biotech IPO allotment will be available on Link Intime’s website.
Click on this link to get allotment status.
Windlas Biotech IPO Registrar
Link Intime India Private Ltd
Link Intime India Private Ltd
C 101, 247 Park, L.B.S.Marg,
Vikhroli (West), Mumbai – 400083
Phone: +91-22-4918 6270
Email: windlas.ipo@linkintime.co.in
Website: http://www.linkintime.co.in
Company Contact Information
Windlas Biotech Limited
40/1, Mohabewala Industrial Area,
Dehradun, 248110
Phone: +91 135 6608000
Email: grievance@windlasbiotech.com
Website: http://www.windlasbiotech.com/
Final thoughts
Windlas Biotech IPO is going to hit Dalal street soon. applying for IPO is purely a personal choice. study well about the company and do subscribe if you are feeling good about the company. I hope this post will give you enough details to make a fundamental study of the company. learn well and make a wise decision.
Happy Investing